首页> 美国卫生研究院文献>Journal of Virology >Amino Acid Residue-Specific Neutralization and Nonneutralization of Hepatitis C Virus by Monoclonal Antibodies to the E2 Protein
【2h】

Amino Acid Residue-Specific Neutralization and Nonneutralization of Hepatitis C Virus by Monoclonal Antibodies to the E2 Protein

机译:通过E2蛋白单克隆抗体对C型肝炎病毒的氨基酸残基特异性中和和非中和

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Antibodies to epitopes in the E2 protein of hepatitis C virus (HCV) reduce the viral infectivity in vivo and in vitro. However, the virus can persist in patients in the presence of neutralizing antibodies. In this study, we generated a panel of monoclonal antibodies that bound specifically to the region between residues 427 and 446 of the E2 protein of HCV genotype 1a, and we examined their capacity to neutralize HCV in a cell culture system. Of the four monoclonal antibodies described here, two were able to neutralize the virus in a genotype 1a-specific manner. The other two failed to neutralize the virus. Moreover, one of the nonneutralizing antibodies could interfere with the neutralizing activity of a chimpanzee polyclonal antibody at E2 residues 412 to 426, as it did with an HCV-specific immune globulin preparation, which was derived from the pooled plasma of chronic hepatitis C patients. Mapping the epitope-paratope contact interfaces revealed that these functionally distinct antibodies shared binding specificity for key amino acid residues, including W437, L438, L441, and F442, within the same epitope of the E2 protein. These data suggest that the effectiveness of antibody-mediated neutralization of HCV could be deduced from the interplay between an antibody and a specific set of amino acid residues. Further understanding of the molecular mechanisms of antibody-mediated neutralization and nonneutralization should provide insights for designing a vaccine to control HCV infection in vivo.
机译:丙型肝炎病毒(HCV)E2蛋白抗原决定簇的抗体可降低体内和体外的病毒感染性。但是,在存在中和抗体的情况下,病毒可以在患者体内持续存在。在这项研究中,我们产生了一组单克隆抗体,这些单克隆抗体与HCV基因型1a的E2蛋白的427位残基和446位残基之间的区域特异性结合,并研究了它们在细胞培养系统中中和HCV的能力。在这里描述的四种单克隆抗体中,有两种能够以基因型1a特异性方式中和病毒。另外两个未能中和该病毒。此外,一种非中和抗体可能会干扰黑猩猩多克隆抗体对E2残基412至426的中和活性,就像HCV特异性免疫球蛋白制剂一样,该制剂源自慢性丙型肝炎患者的血浆。映射表位-对位接触界面显示,这些功能不同的抗体对关键氨基酸残基具有共享特异性,包括W 437 ,L 438 ,L 441 442 位于E2蛋白的同一表位中。这些数据表明,抗体介导的HCV中和作用的有效性可以从抗体和一组特定的氨基酸残基之间的相互作用中推论得出。对抗体介导的中和和非中和的分子机制的进一步了解应为设计疫苗控制体内HCV感染提供见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号